Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

  • Ellen Weisberg ,

    Contributed equally to this work with: Ellen Weisberg, Qingsong Liu

    ellen_weisberg@dfci.harvard.edu (EW); james_griffin@dfci.harvard.edu (JDG)

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Qingsong Liu ,

    Contributed equally to this work with: Ellen Weisberg, Qingsong Liu

    Affiliation Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Xin Zhang,

    Affiliation Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Erik Nelson,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Martin Sattler,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Feiyang Liu,

    Affiliation High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, Anhui, P.R. China

    ⨯
  • Maria Nicolais,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Jianming Zhang,

    Affiliation Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Constantine Mitsiades,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Robert W. Smith,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Richard Stone,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Ilene Galinsky,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Atsushi Nonami,

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • James D. Griffin ,

    ellen_weisberg@dfci.harvard.edu (EW); james_griffin@dfci.harvard.edu (JDG)

    Affiliation Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯
  • Nathanael Gray

    Affiliation Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America

    ⨯

Viewed

Cited

Saved

Discussed

Powered by Altmetric
Questions or concerns about usage data? Please let us know.